全國服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡(jiǎn)要描述：Lacidipine 103890-78-4Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker.Lacidipine, a novel third-generation dihydropyridine calcium channel blocker
產(chǎn)品型號(hào)：abs47027694廠商性質(zhì)：生產(chǎn)廠家更新時(shí)間：2025-12-25訪 問 量：533產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 103890-78-4 |
|---|---|---|---|
| 分子式 | C26H33NO6 | 純度 | 99% |
| 分子量 | 455.54 | 貨號(hào) | abs47027694 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a L-type calcium channel blocker | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Lacidipine 103890-78-4
| 產(chǎn)品描述 | |
| 描述 | Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker.Lacidipine, a novel third-generation dihydropyridine calcium channel blocker, has been demonstrated effective for hypertension. lacidipine protects HKCs against apoptosis induced by ATP depl |
| 純度 | 99% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 拉西di平 |
| 外觀 | 白色至灰白色結(jié)晶固體 |
| 可溶性/溶解性 | DMSO : 84 mg/mL (184.4 mM) Ethanol : 21 mg/mL (46.1 mM) |
| 生物活性 | |
| 靶點(diǎn) | L-type calcium channel |
| In vitro(體外研究) | Lacidipine, an L-type Ca(2+) channel blocker that also inhibits (ER) efflux, enhances folding, trafficking, and activity of degradation-prone glucocerebrosidase (GC) variants. Lacidipine remodels mutated GC proteostasis by simultaneously activating a series of distinct molecular mechanisms, namely modulation of Ca(2+) homeostasis, upregulation of the ER chaperone BiP, and moderate induction of the unfolded protein response. Lacidipine almost completely inhibits cholesterol esterification in cholesterol loaded mouse cultured peritoneal macrophages. |
| In vivo(體內(nèi)研究) | Lacidipine has non-significant effects on blood pressure but inhibits the paradoxical increases in plasma renin activity (PRA) and in renin mRNA in kidney that are found in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP). Lacidipine restores the physiological downregulation of renin production by high salt and reduces left ventricular hypertrophy and mRNA levels of atrial natriuretic factor and transforming growth factor-beta1. Lacidipine (1 and 3 mg/kg) also effectively increases calcium concentrations significantly in ovariectomized rats. Lacidipine, a dihydropyridine-type calcium antagonist, reduces the cardiac hypertrophy and the cardiacendothelin-1 (ET-1) gene overexpression occurring in salt-loaded stroke-prone spontaneously hypertensive rats (SL-SHRSP), an effect occurring without systolic blood pressure (SBP) change. Lacidipine exerts a dose-related inhibition of ventricle hypertrophy and preproET-1-mRNA expression in SHRSP and indicate that this effect is unrelated to SBP changes. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Cardiovascular Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號(hào)申江科創(chuàng)園18棟
郵箱：
傳真：